Skip to content
2000
Volume 14, Issue 1
  • ISSN: 2210-6812
  • E-ISSN: 2210-6820

Abstract

The use of mRNA in therapeutics has lately emerged as a powerful strategy for alleviating the various viral infections and diseased conditions, along with prophylaxis. However, a key challenge in their efficient delivery is the protection of the nucleic acid from degradation followed by mRNA transport to the cells. In this regard, clinical translation of mRNA therapeutics has largely been facilitated with the advent of lipid-based nanoparticles (LBNPs). LBNPs–mRNA vaccines currently being employed for COVID-19 is one such instance substantiating and endorsing the use of lipidic nanocarriers for mRNA therapeutics. Thus, the current review article aims to furnish information on developmental challenges, different aspects of lipid-based carrier systems for mRNA delivery, their vital applications in different diseases and the future potential of LBNPs in therapeutics.

Loading

Article metrics loading...

/content/journals/nanoasi/10.2174/0122106812284202231228095045
2024-02-01
2025-09-12
Loading full text...

Full text loading...

/content/journals/nanoasi/10.2174/0122106812284202231228095045
Loading

  • Article Type:
    Review Article
Keyword(s): cancer; COVID-19; lipid-based carrier system; RNA; stability; vaccine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test